<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664946</url>
  </required_header>
  <id_info>
    <org_study_id>k（2020）31</org_study_id>
    <nct_id>NCT04664946</nct_id>
  </id_info>
  <brief_title>Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)</brief_title>
  <official_title>Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT): One Single Center, Safety and Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hui-Sheng Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute&#xD;
      ischemic stroke patients who missed recanalization operation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of server adverse events</measure>
    <time_frame>48 hours</time_frame>
    <description>server adverse events including femoral artery dissection, local thrombosis, seudoaneurysm, arteriovenousfistula, etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 1</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of patients with modified Rankin Score 0 to 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 2</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of patients with modified Rankin Score 0 to 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score</measure>
    <time_frame>90 days</time_frame>
    <description>Modified Rankin Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in national institutes of health stroke scale (NIHSS)</measure>
    <time_frame>48 hours</time_frame>
    <description>Decrease in NIHSS scoring at 48 hours after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of symptomatic intracranial hemorrhage (sICH)</measure>
    <time_frame>48 hours</time_frame>
    <description>sICH was defined as 4 or more increase in NIHSS caused by hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of intraparenchymal hemorrhage (PH1 and PH2)</measure>
    <time_frame>48 hours</time_frame>
    <description>Proportion of intraparenchymal hemorrhage (PH1 and PH2) within 48 hours after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cerebral edema</measure>
    <time_frame>48 hours</time_frame>
    <description>Cerebral edema was determined by cerebral volume or midline shift</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All causes of death within 48 hours after the treatment</measure>
    <time_frame>48 hours</time_frame>
    <description>All causes of death within 48 hours after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in serum factors levels in different artery region</measure>
    <time_frame>0 hour</time_frame>
    <description>Differences in serum factors levels in different Bessel region before recanalization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Neuroprotection</condition>
  <arm_group>
    <arm_group_label>Intra-arterial administration of 3-n-butylphthalide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-arterial administration of neuroprotective agents</intervention_name>
    <description>Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.</description>
    <arm_group_label>Intra-arterial administration of 3-n-butylphthalide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years;&#xD;
&#xD;
          2. Major neurologic deficits: 6≤NIHSS≤20;&#xD;
&#xD;
          3. Missing recanalization therapy (IVT or EVT) or progressive stroke, which was defined&#xD;
             as symptoms worsen in 48 hours (an increase in NIHSS more than 4);&#xD;
&#xD;
          4. Premorbid mRS 0 or 1;&#xD;
&#xD;
          5. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Modified Rankin Score &gt;2 caused by a history of prior stroke;&#xD;
&#xD;
          2. Patients who underwent intravenous thrombolysis or Endovascular treatment;&#xD;
&#xD;
          3. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ &lt;80000/mm3;&#xD;
&#xD;
          4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of&#xD;
             upper limit of normal value), increase in serum creatinine (more than 1.5 times of&#xD;
             upper limit of normal value) or requiring dialysis;&#xD;
&#xD;
          5. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure&#xD;
             over 110 mmHg);&#xD;
&#xD;
          6. Unsuitable for this clinical studies assessed by researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Neurology, General Hospital of Northern Theater Command</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroprotective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

